Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999

Franck Rapaport; Kenneth Seier; Yaseswini Neelamraju; Duane Hassane; Timour Baslan; Daniel T. Gildea; Samuel Haddox; Tak Lee; H. Moses Murdock; Caroline Sheridan; Alexis Thurmond; Ling Wang; Martin Carroll; Larry D. Cripe; Hugo Fernandez; Christopher E. Mason; Elisabeth Paietta; Gail J. Roboz; Zhuoxin Sun; Martin S. Tallman; Yanming Zhang; Mithat Gönen; Ross Levine; Ari M. Melnick; Maria Kleppe; Francine E. Garrett-Bakelman

doi:10.1038/s41408-022-00736-z

Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999

Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, Duane Hassane, Timour Baslan, Daniel T. Gildea, Samuel Haddox, Tak Lee, H. Moses Murdock, Caroline Sheridan, Alexis Thurmond, Ling Wang, Martin Carroll, Larry D. Cripe, Hugo Fernandez, Christopher E. Mason, Elisabeth Paietta, Gail J. Roboz, Zhuoxin Sun, Martin S. TallmanYanming Zhang, Mithat Gönen, Ross Levine, Ari M. Melnick, Maria Kleppe, Francine E. Garrett-Bakelman^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Article number	137
Journal	Blood cancer journal
Volume	12
Issue number	9
DOIs	https://doi.org/10.1038/s41408-022-00736-z
State	Published - Sep 2022

Funding

The authors thank the following funding sources: UVA Cancer Center through the NCI Cancer Center Support Grant P30 CA44579, the University of Virginia, funding from the American Society of Hematology (ASHAMFDP-20121) under the ASH-AMFDP partnership with The Robert Wood Johnson Foundation, Leukemia Research Foundation Young Investigator award, and U10 5U10CA180827 subaward to FGB. Partial support UL1 TR001866 from the National Center for Advancing Translational Sciences, National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program to FR. TB was supported by the William C. and Joyce C. O’Neil Charitable Trust, Memorial Sloan Kettering Single Cell Sequencing Initiative. Evans foundation grant to AMM. The authors thank the following service providers: Next generation sequencing services were provided by the New York Genome Center and Weill Cornell Medicine Genomics Resources Core Facility. Flow sorting services were provided by the Memorial Sloan Kettering Cancer Center’s Flow Cytometry Core Facility. Computational resources and technical support were provided by the Weill Cornell Medicine Applied Bioinformatics core, the Memorial Sloan Kettering Cancer Center Bioinformatics core, and the School of Medicine Research Computing group at The University of Virginia. Daniel Gildea is currently affiliated with MedStar Georgetown University Hospital, Maria Kleppe is currently affiliated with Imago Biosciences, Inc., Tak Lee is currently affiliated with The Rockefeller University, H. Moses Murdock is currently affiliated with Harvard Medical School/Brigham and Women’s Hospital, Franck Rapaport is currently affiliated with Sanofi, Caroline Sheridan is currently affiliated with Immunai, and Martin S. Tallman is currently affiliated with Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center. This study was conducted by the ECOG-ACRIN Cancer Research Group (Peter J. O’Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs). The study was supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180827, CA180820, CA233290, CA189859, CA233321, CA233270, U10CA180820, U10CA180794, UG1CA189859, and UG1CA233290. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or ECOG-ACRIN, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. The authors thank the following funding sources: UVA Cancer Center through the NCI Cancer Center Support Grant P30 CA44579, the University of Virginia, funding from the American Society of Hematology (ASHAMFDP-20121) under the ASH-AMFDP partnership with The Robert Wood Johnson Foundation, Leukemia Research Foundation Young Investigator award, and U10 5U10CA180827 subaward to FGB. Partial support UL1 TR001866 from the National Center for Advancing Translational Sciences, National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program to FR. TB was supported by the William C. and Joyce C. O’Neil Charitable Trust, Memorial Sloan Kettering Single Cell Sequencing Initiative. Evans foundation grant to AMM. The authors thank the following service providers: Next generation sequencing services were provided by the New York Genome Center and Weill Cornell Medicine Genomics Resources Core Facility. Flow sorting services were provided by the Memorial Sloan Kettering Cancer Center’s Flow Cytometry Core Facility. Computational resources and technical support were provided by the Weill Cornell Medicine Applied Bioinformatics core, the Memorial Sloan Kettering Cancer Center Bioinformatics core, and the School of Medicine Research Computing group at The University of Virginia. Daniel Gildea is currently affiliated with MedStar Georgetown University Hospital, Maria Kleppe is currently affiliated with Imago Biosciences, Inc., Tak Lee is currently affiliated with The Rockefeller University, H. Moses Murdock is currently affiliated with Harvard Medical School/Brigham and Women’s Hospital, Franck Rapaport is currently affiliated with Sanofi, Caroline Sheridan is currently affiliated with Immunai, and Martin S. Tallman is currently affiliated with Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center. This study was conducted by the ECOG-ACRIN Cancer Research Group (Peter J. O’Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs). The study was supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180827, CA180820, CA233290, CA189859, CA233321, CA233270, U10CA180820, U10CA180794, UG1CA189859, and UG1CA233290. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or ECOG-ACRIN, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.

ASJC Scopus subject areas

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41408-022-00736-z

Cite this

Rapaport, F., Seier, K., Neelamraju, Y., Hassane, D., Baslan, T., Gildea, D. T., Haddox, S., Lee, T., Murdock, H. M., Sheridan, C., Thurmond, A., Wang, L., Carroll, M., Cripe, L. D., Fernandez, H., Mason, C. E., Paietta, E., Roboz, G. J., Sun, Z., ... Garrett-Bakelman, F. E. (2022). Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999. Blood cancer journal, 12(9), Article 137. https://doi.org/10.1038/s41408-022-00736-z

@article{e0fd6daa4c954ce980674b1d48ea4f10,

title = "Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group{\textquoteright}s clinical trial E3999",

author = "Franck Rapaport and Kenneth Seier and Yaseswini Neelamraju and Duane Hassane and Timour Baslan and Gildea, {Daniel T.} and Samuel Haddox and Tak Lee and Murdock, {H. Moses} and Caroline Sheridan and Alexis Thurmond and Ling Wang and Martin Carroll and Cripe, {Larry D.} and Hugo Fernandez and Mason, {Christopher E.} and Elisabeth Paietta and Roboz, {Gail J.} and Zhuoxin Sun and Tallman, {Martin S.} and Yanming Zhang and Mithat G{\"o}nen and Ross Levine and Melnick, {Ari M.} and Maria Kleppe and Garrett-Bakelman, {Francine E.}",

note = "Funding Information: The authors thank the following funding sources: UVA Cancer Center through the NCI Cancer Center Support Grant P30 CA44579, the University of Virginia, funding from the American Society of Hematology (ASHAMFDP-20121) under the ASH-AMFDP partnership with The Robert Wood Johnson Foundation, Leukemia Research Foundation Young Investigator award, and U10 5U10CA180827 subaward to FGB. Partial support UL1 TR001866 from the National Center for Advancing Translational Sciences, National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program to FR. TB was supported by the William C. and Joyce C. O{\textquoteright}Neil Charitable Trust, Memorial Sloan Kettering Single Cell Sequencing Initiative. Evans foundation grant to AMM. The authors thank the following service providers: Next generation sequencing services were provided by the New York Genome Center and Weill Cornell Medicine Genomics Resources Core Facility. Flow sorting services were provided by the Memorial Sloan Kettering Cancer Center{\textquoteright}s Flow Cytometry Core Facility. Computational resources and technical support were provided by the Weill Cornell Medicine Applied Bioinformatics core, the Memorial Sloan Kettering Cancer Center Bioinformatics core, and the School of Medicine Research Computing group at The University of Virginia. Daniel Gildea is currently affiliated with MedStar Georgetown University Hospital, Maria Kleppe is currently affiliated with Imago Biosciences, Inc., Tak Lee is currently affiliated with The Rockefeller University, H. Moses Murdock is currently affiliated with Harvard Medical School/Brigham and Women{\textquoteright}s Hospital, Franck Rapaport is currently affiliated with Sanofi, Caroline Sheridan is currently affiliated with Immunai, and Martin S. Tallman is currently affiliated with Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center. This study was conducted by the ECOG-ACRIN Cancer Research Group (Peter J. O{\textquoteright}Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs). The study was supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180827, CA180820, CA233290, CA189859, CA233321, CA233270, U10CA180820, U10CA180794, UG1CA189859, and UG1CA233290. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or ECOG-ACRIN, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. Funding Information: The authors thank the following funding sources: UVA Cancer Center through the NCI Cancer Center Support Grant P30 CA44579, the University of Virginia, funding from the American Society of Hematology (ASHAMFDP-20121) under the ASH-AMFDP partnership with The Robert Wood Johnson Foundation, Leukemia Research Foundation Young Investigator award, and U10 5U10CA180827 subaward to FGB. Partial support UL1 TR001866 from the National Center for Advancing Translational Sciences, National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program to FR. TB was supported by the William C. and Joyce C. O{\textquoteright}Neil Charitable Trust, Memorial Sloan Kettering Single Cell Sequencing Initiative. Evans foundation grant to AMM. The authors thank the following service providers: Next generation sequencing services were provided by the New York Genome Center and Weill Cornell Medicine Genomics Resources Core Facility. Flow sorting services were provided by the Memorial Sloan Kettering Cancer Center{\textquoteright}s Flow Cytometry Core Facility. Computational resources and technical support were provided by the Weill Cornell Medicine Applied Bioinformatics core, the Memorial Sloan Kettering Cancer Center Bioinformatics core, and the School of Medicine Research Computing group at The University of Virginia. Daniel Gildea is currently affiliated with MedStar Georgetown University Hospital, Maria Kleppe is currently affiliated with Imago Biosciences, Inc., Tak Lee is currently affiliated with The Rockefeller University, H. Moses Murdock is currently affiliated with Harvard Medical School/Brigham and Women{\textquoteright}s Hospital, Franck Rapaport is currently affiliated with Sanofi, Caroline Sheridan is currently affiliated with Immunai, and Martin S. Tallman is currently affiliated with Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center. This study was conducted by the ECOG-ACRIN Cancer Research Group (Peter J. O{\textquoteright}Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs). The study was supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180827, CA180820, CA233290, CA189859, CA233321, CA233270, U10CA180820, U10CA180794, UG1CA189859, and UG1CA233290. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or ECOG-ACRIN, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. ",

year = "2022",

month = sep,

doi = "10.1038/s41408-022-00736-z",

language = "English (US)",

volume = "12",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "9",

}

Rapaport, F, Seier, K, Neelamraju, Y, Hassane, D, Baslan, T, Gildea, DT, Haddox, S, Lee, T, Murdock, HM, Sheridan, C, Thurmond, A, Wang, L, Carroll, M, Cripe, LD, Fernandez, H, Mason, CE, Paietta, E, Roboz, GJ, Sun, Z, Tallman, MS, Zhang, Y, Gönen, M, Levine, R, Melnick, AM, Kleppe, M & Garrett-Bakelman, FE 2022, 'Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999', Blood cancer journal, vol. 12, no. 9, 137. https://doi.org/10.1038/s41408-022-00736-z

TY - JOUR

T1 - Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999

AU - Rapaport, Franck

AU - Seier, Kenneth

AU - Neelamraju, Yaseswini

AU - Hassane, Duane

AU - Baslan, Timour

AU - Gildea, Daniel T.

AU - Haddox, Samuel

AU - Lee, Tak

AU - Murdock, H. Moses

AU - Sheridan, Caroline

AU - Thurmond, Alexis

AU - Wang, Ling

AU - Carroll, Martin

AU - Cripe, Larry D.

AU - Fernandez, Hugo

AU - Mason, Christopher E.

AU - Paietta, Elisabeth

AU - Roboz, Gail J.

AU - Sun, Zhuoxin

AU - Tallman, Martin S.

AU - Zhang, Yanming

AU - Gönen, Mithat

AU - Levine, Ross

AU - Melnick, Ari M.

AU - Kleppe, Maria

AU - Garrett-Bakelman, Francine E.

N1 - Funding Information: The authors thank the following funding sources: UVA Cancer Center through the NCI Cancer Center Support Grant P30 CA44579, the University of Virginia, funding from the American Society of Hematology (ASHAMFDP-20121) under the ASH-AMFDP partnership with The Robert Wood Johnson Foundation, Leukemia Research Foundation Young Investigator award, and U10 5U10CA180827 subaward to FGB. Partial support UL1 TR001866 from the National Center for Advancing Translational Sciences, National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program to FR. TB was supported by the William C. and Joyce C. O’Neil Charitable Trust, Memorial Sloan Kettering Single Cell Sequencing Initiative. Evans foundation grant to AMM. The authors thank the following service providers: Next generation sequencing services were provided by the New York Genome Center and Weill Cornell Medicine Genomics Resources Core Facility. Flow sorting services were provided by the Memorial Sloan Kettering Cancer Center’s Flow Cytometry Core Facility. Computational resources and technical support were provided by the Weill Cornell Medicine Applied Bioinformatics core, the Memorial Sloan Kettering Cancer Center Bioinformatics core, and the School of Medicine Research Computing group at The University of Virginia. Daniel Gildea is currently affiliated with MedStar Georgetown University Hospital, Maria Kleppe is currently affiliated with Imago Biosciences, Inc., Tak Lee is currently affiliated with The Rockefeller University, H. Moses Murdock is currently affiliated with Harvard Medical School/Brigham and Women’s Hospital, Franck Rapaport is currently affiliated with Sanofi, Caroline Sheridan is currently affiliated with Immunai, and Martin S. Tallman is currently affiliated with Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center. This study was conducted by the ECOG-ACRIN Cancer Research Group (Peter J. O’Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs). The study was supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180827, CA180820, CA233290, CA189859, CA233321, CA233270, U10CA180820, U10CA180794, UG1CA189859, and UG1CA233290. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or ECOG-ACRIN, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. Funding Information: The authors thank the following funding sources: UVA Cancer Center through the NCI Cancer Center Support Grant P30 CA44579, the University of Virginia, funding from the American Society of Hematology (ASHAMFDP-20121) under the ASH-AMFDP partnership with The Robert Wood Johnson Foundation, Leukemia Research Foundation Young Investigator award, and U10 5U10CA180827 subaward to FGB. Partial support UL1 TR001866 from the National Center for Advancing Translational Sciences, National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program to FR. TB was supported by the William C. and Joyce C. O’Neil Charitable Trust, Memorial Sloan Kettering Single Cell Sequencing Initiative. Evans foundation grant to AMM. The authors thank the following service providers: Next generation sequencing services were provided by the New York Genome Center and Weill Cornell Medicine Genomics Resources Core Facility. Flow sorting services were provided by the Memorial Sloan Kettering Cancer Center’s Flow Cytometry Core Facility. Computational resources and technical support were provided by the Weill Cornell Medicine Applied Bioinformatics core, the Memorial Sloan Kettering Cancer Center Bioinformatics core, and the School of Medicine Research Computing group at The University of Virginia. Daniel Gildea is currently affiliated with MedStar Georgetown University Hospital, Maria Kleppe is currently affiliated with Imago Biosciences, Inc., Tak Lee is currently affiliated with The Rockefeller University, H. Moses Murdock is currently affiliated with Harvard Medical School/Brigham and Women’s Hospital, Franck Rapaport is currently affiliated with Sanofi, Caroline Sheridan is currently affiliated with Immunai, and Martin S. Tallman is currently affiliated with Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center. This study was conducted by the ECOG-ACRIN Cancer Research Group (Peter J. O’Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs). The study was supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180827, CA180820, CA233290, CA189859, CA233321, CA233270, U10CA180820, U10CA180794, UG1CA189859, and UG1CA233290. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or ECOG-ACRIN, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.

PY - 2022/9

Y1 - 2022/9

UR - http://www.scopus.com/inward/record.url?scp=85138459307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138459307&partnerID=8YFLogxK

U2 - 10.1038/s41408-022-00736-z

DO - 10.1038/s41408-022-00736-z

M3 - Letter

C2 - 36151075

AN - SCOPUS:85138459307

SN - 2044-5385

VL - 12

JO - Blood cancer journal

JF - Blood cancer journal

IS - 9

M1 - 137

ER -

Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this